The National Surgical Adjuvant Breast and Bowel Project (NSABP) is an NCI-funded clinical trials cooperative group for cancer treatment and prevention and control research. The group has a more than 40-year history of conducting large-scale controlled treatment trials that have improved the outcome for patients with breast or colorectal cancer and have provided a better understanding of tumor biology. In 1992, the NSABP extended its research agenda to include cancer prevention trials. The NSABP has been a CCOP Research Base since the inception of the CCOP Program and 45 CCOPs and 8 MBCCOPs currently list the NSABP among their research bases. CCOP participation in NSABP treatment and prevention trials is substantial;approximately 30% of NSABP accrual is attributable to CCOP investigators. This application requests continued funding for the NSABP to continue as a CCOP Research Base for the period of June 1, 2012, through May 31, 2017. During the proposed grant period, the NSABP will 1) continue to design and implement multi-institutional cancer treatment and prevention and control clinical trials;2) analyze, report, and publish the results of current NSABP studies;3) implement recruitment mechanisms and procedures to achieve adequate accrual and foster the participation of women and minorities in NSABP clinical trials;4) maintain data collection, data monitoring, and quality control procedures that are in compliance with federal guidelines;5) monitor CCOP performance through ongoing quality assurance programs;and, 6) continue the integration of CCOP investigators into the overall functioning of the NSABP.

Public Health Relevance

Breast and bowel represents a major public health issue with a combined incidence of 361,530 cases in the United States in 2010 and more than 96,140 deaths attributed to the cancers. The NSABP has a 50+ year history of conducting high quality cancer, treatment, prevention, and control clinical trials that have substantially improved the survival and the quality of life of individuals with these diseases. This application will allow th NSABP to continue this important research that has the potential to impact the care of women and men in the United States and around the world.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA037377-27S1
Application #
8681581
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
Mooney, Margaret M
Project Start
1983-09-15
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
27
Fiscal Year
2013
Total Cost
$646,933
Indirect Cost
$90,192
Name
Nsabp Foundation, Inc.
Department
Type
DUNS #
107186988
City
Pittsburgh
State
PA
Country
United States
Zip Code
15212
O'Connell, Michael J; Colangelo, Linda H; Beart, Robert W et al. (2014) Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 32:1927-34
Aebi, Stefan; Gelber, Shari; Anderson, Stewart J et al. (2014) Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol 15:156-63
Gonsalves, Wilson I; Mahoney, Michelle R; Sargent, Daniel J et al. (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 106:
Sha, Dan; Lee, Adam M; Shi, Qian et al. (2014) Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res 20:3319-27
Land, Stephanie R; Liu, Qing; Wickerham, D Lawrence et al. (2014) Cigarette smoking, physical activity, and alcohol consumption as predictors of cancer incidence among women at high risk of breast cancer in the NSABP P-1 trial. Cancer Epidemiol Biomarkers Prev 23:823-32
Lee, Minjung; Dignam, James J; Han, Junhee (2014) Multiple imputation methods for nonparametric inference on cumulative incidence with missing cause of failure. Stat Med 33:4605-26
Klepin, Heidi D; Geiger, Ann M; Bandos, Hanna et al. (2014) Cognitive factors associated with adherence to oral antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study. Cancer Prev Res (Phila) 7:161-8
Han, Baoguang; Yu, Menggang; Dignam, James J et al. (2014) Bayesian approach for flexible modeling of semicompeting risks data. Stat Med 33:5111-25
Lembersky, Barry C; Rastogi, Priya (2014) HER2 targeting in early breast cancer: more options and more questions. Oncology (Williston Park) 28:293-4
Huang, Jocelin; Nair, Suresh G; Mahoney, Michelle R et al. (2014) Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13:100-9

Showing the most recent 10 out of 191 publications